Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Gliosarcoma 3Glioma 3Glioblastoma 3Dendritic Cell Sarcoma, Interdigitating 3Oligodendroglioma 2Astrocytoma 2Sarcoma, Kaposi 1Recurrence 1Neuroectodermal Tumors, Primitive 1Meningioma 1Lymphoma 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Heart Failure 1HIV Infections 1Erdheim-Chester Disease 1Ependymoma 1Central Nervous System Neoplasms 1Cardiotoxicity 1Brain Neoplasms 1AIDS-related Kaposi sarcoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1pembrolizumab 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1cobimetinib 1X-Rays 1Vemurafenib 1Radiation Dose Hypofractionation 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Lenalidomide 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytic Sarcoma × Lenalidomide × Sarcoma × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡